SCHEMBL3404838

SCHEMBL3404838

Cc1nc(-c2cccc3ccccc23)[nH]c1CN1CCN(C(C)C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
ACHE P22303 1/20 0.39
MC4R P32245 3/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TNIK Q9UKE5 1/20 0.37
SLC2A1 P11166 1/20 0.37
MAOB P27338 4/20 0.37
TACR2 P21452 2/20 0.37
PARP1 P09874 2/20 0.37
PI4KA P42356 1/20 0.36
PI4K2B Q8TCG2 1/20 0.36
PI4K2A Q9BTU6 1/20 0.36
PI4KB Q9UBF8 1/20 0.36
VCP P55072 1/20 0.36
KDM4E B2RXH2 1/20 0.36
TACR3 P29371 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3399467 0.82 DRD4 (0.46) LMNAACHEMC4RTNIKSLC2A1
SCHEMBL3400861 0.81 SIGMAR1 (0.43) LMNAACHEALDH1A1POLBMAPT
SCHEMBL3396848 0.81 SIGMAR1 (0.46) LMNAACHEMC4RALDH1A1MAPK1
SCHEMBL3406108 0.78 DRD4 (0.42) LMNAACHEMC4RTNIKSLC2A1
SCHEMBL3405519 0.75 KDM4E (0.41) LMNAACHEMC4RALDH1A1POLB
SCHEMBL3400819 0.75 HTR2C (0.46) LMNAALDH1A1SLC2A1MAOBKDM4E
SCHEMBL3401421 0.74 MAOB (0.40) LMNAACHEMC4RALDH1A1POLB
SCHEMBL3404703 0.73 PI4KA (0.45) ALDH1A1PI4KAPI4K2BPI4K2API4KB
SCHEMBL3402431 0.73 CCND1 (0.40) LMNAACHEMC4RSLC2A1MAOB
SCHEMBL10037140 0.72 ACHE (0.61) ACHEMC4RALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 LMNA 4548/4885ACHE 422/4885MC4R 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.